Introduction
What treatments are used for Central sleep apnea? The main approaches include treating any underlying disorder that is disrupting breathing control, using positive airway pressure therapies such as CPAP or adaptive servo-ventilation, in some cases prescribing supplemental oxygen or selected medications, and occasionally using implantable or procedural interventions. These treatments are aimed at the physiology of breathing control rather than the airway alone, because central sleep apnea occurs when the brain intermittently fails to generate an appropriate respiratory effort during sleep.
Central sleep apnea is managed by trying to stabilize the signaling between the brain, blood gases, respiratory muscles, and sleep state. Some therapies reduce the frequency of pauses in breathing by supporting ventilation directly, while others reduce the triggers that make breathing unstable. The overall aim is to decrease symptoms such as fragmented sleep and daytime sleepiness, reduce physiologic stress from repeated oxygen drops and arousals, and restore more regular breathing during sleep.
Understanding the Treatment Goals
The main goals of treatment are to reduce apnea episodes, improve sleep continuity, and correct the physiologic instability that produces central pauses. Unlike obstructive sleep apnea, where the airway collapses, central sleep apnea reflects a failure of respiratory drive. Treatment therefore focuses on the control system for breathing: the sensitivity of the brainstem respiratory centers to carbon dioxide and oxygen, the responsiveness of ventilation, and any medical condition that is interfering with this regulation.
Another goal is to prevent downstream effects of repetitive sleep disruption. Recurrent central apneas can lower oxygen levels, trigger sympathetic nervous system activation, and fragment sleep architecture. Over time, this can worsen cardiovascular strain, impair daytime alertness, and reduce quality of life. Treatment decisions are shaped by whether the goal is to treat a reversible cause, stabilize breathing in a chronic condition, or reduce complications associated with prolonged nocturnal hypoventilation and desaturation.
Common Medical Treatments
Positive airway pressure therapy is one of the most common treatment categories. Continuous positive airway pressure, or CPAP, delivers a steady stream of pressurized air through a mask. In central sleep apnea, CPAP does not mainly work by splinting open a collapsed airway, because the core problem is absent respiratory effort. Instead, CPAP can sometimes stabilize breathing by improving lung volume, reducing upper airway resistance, and smoothing the interaction between airflow, carbon dioxide levels, and respiratory drive. In some patients, especially those with mixed obstructive and central events or central events that emerge during treatment of obstructive sleep apnea, CPAP reduces ventilatory instability enough to lessen central apneas.
Adaptive servo-ventilation, or ASV, is designed specifically for unstable breathing patterns. It continuously monitors the patient’s breathing and adjusts pressure support breath by breath. When ventilation drops, the device increases support; when breathing becomes excessive, it reduces support. This mechanism targets the oscillation known as ventilatory instability or loop gain, which is a key physiologic contributor to central apnea. By preventing overcorrection and undercorrection in ventilation, ASV helps maintain carbon dioxide levels in a range that keeps the brain’s respiratory drive more stable.
Bilevel positive airway pressure may also be used in selected cases. It delivers higher pressure during inhalation and lower pressure during exhalation, increasing ventilatory assistance. In some individuals with central apneas related to hypoventilation, respiratory muscle weakness, or neurologic disease, bilevel support can improve minute ventilation and reduce the tendency for carbon dioxide to fall below the apnea threshold. The benefit comes from augmenting ventilation rather than correcting a structural airway obstruction.
Supplemental oxygen can reduce central apnea frequency in certain patients. Oxygen increases arterial oxygen saturation and may blunt the instability of breathing control by reducing the drive fluctuations that occur when oxygen levels drop. In some forms of central sleep apnea, especially those associated with heart failure or periodic breathing, oxygen can lower chemoreceptor overactivity and reduce the cycle of hyperventilation and apnea. The effect is physiologic stabilization rather than mechanical support.
Medications are used in more limited circumstances. Acetazolamide is one of the better known examples. It causes a mild metabolic acidosis by promoting bicarbonate loss in the kidneys. This slight acidification increases baseline respiratory drive and can help prevent carbon dioxide from falling too low during sleep, making central pauses less likely. Other medications may be considered when central apnea is related to specific conditions, such as opioid use or high-altitude exposure, but the underlying rationale remains the same: modify the respiratory control system so it is less likely to overshoot and undershoot ventilation.
When central sleep apnea is secondary to another disease, treatment of the underlying condition is often the most effective medical strategy. For example, optimizing heart failure therapy can reduce circulatory delay and pulmonary congestion, both of which contribute to unstable ventilatory feedback. In patients with neurologic disease, addressing the disorder may limit further disruption of respiratory centers. In opioid-related central apnea, reducing or changing the respiratory-depressant exposure can improve the brain’s ability to generate regular breaths during sleep.
Procedures or Interventions
Certain procedures are used when standard medical therapies are inadequate or when the cause of central sleep apnea suggests a more targeted intervention. One important option is transvenous phrenic nerve stimulation, an implantable therapy that activates the phrenic nerve during sleep to trigger diaphragmatic contraction. The device senses breathing instability and stimulates the diaphragm in a timed pattern, effectively substituting controlled mechanical breathing efforts for absent central respiratory drive. This does not restore brain signaling directly, but it bypasses the failure point by producing regular ventilation.
Phrenic nerve stimulation is generally considered in adults with moderate to severe central sleep apnea who do not respond adequately to noninvasive treatments or who cannot tolerate mask-based therapies. It is especially useful when the disorder is persistent and the pattern of breathing instability is not adequately controlled by CPAP or oxygen. The physiologic effect is to create a more regular breathing rhythm and reduce the repeated oxygen desaturations and arousals caused by apneas.
Procedural approaches may also include careful management of conditions that mechanically or neurologically affect breathing control. For example, patients with brainstem lesions, severe structural neurologic disease, or sleep-related hypoventilation syndromes may require specialized ventilatory support strategies or evaluation for broader neurologic or respiratory interventions. In these situations, the procedure or intervention is directed at the pathway that is disrupting central respiratory rhythm generation.
Supportive or Long-Term Management Approaches
Long-term management often involves ongoing reassessment rather than a single fixed treatment. Central sleep apnea can change when the underlying condition changes, so repeated evaluation of sleep-breathing patterns is commonly needed. Follow-up testing helps determine whether the treatment is reducing apnea frequency, normalizing oxygenation, and improving sleep continuity. The physiologic purpose of monitoring is to detect persistent ventilatory instability or treatment-emergent central apneas that may require a different approach.
Supportive management also includes addressing contributors that alter respiratory control. Heart failure management, neurologic care, and adjustment of medications that depress respiration are examples of broader clinical strategies that affect the biological drivers of central apnea. The goal is not merely to treat nocturnal symptoms but to alter the upstream physiology that produces them.
Sleep position, altitude exposure, and sleep-wake regularity can influence breathing stability in some individuals. While these factors are not usually the primary treatment, they can affect ventilatory control by changing oxygen availability, chemoreceptor stimulation, and sleep architecture. In the context of long-term management, the emphasis is on reducing physiologic conditions that intensify breathing oscillations.
Factors That Influence Treatment Choices
Treatment varies according to the severity of the disorder, the pattern of apneas, and whether the central apnea is primary or secondary to another condition. Mild cases may be observed or managed by treating the underlying cause first, while more severe cases often require a device-based therapy that stabilizes ventilation. The degree of oxygen desaturation, the frequency of arousals, and the presence of daytime symptoms all influence how aggressively the breathing instability is addressed.
Age and overall health matter because they affect tolerance of certain treatments and the causes most likely to be present. Heart failure, stroke, chronic opioid use, renal disease, and neurologic disorders each shift treatment selection toward the most relevant physiological mechanism. For example, a patient whose central apnea is driven by heart failure-related circulatory delay may respond differently from someone whose problem is opioid-induced suppression of the brain’s respiratory centers.
Previous treatment response is also important. If CPAP improves obstructive events but central apneas persist, a more targeted therapy such as ASV, oxygen, or phrenic nerve stimulation may be considered. If a medication or underlying condition changes over time, the balance of respiratory control can change as well, making follow-up and therapy adjustment necessary. The choice of treatment therefore reflects both the cause of the apnea and the degree to which the respiratory control system can be stabilized.
Potential Risks or Limitations of Treatment
Each treatment has limitations that follow from its mechanism. CPAP may not fully correct central apnea because it provides pressure support without directly replacing the absent central respiratory drive. In some patients, it can even reveal or worsen central events initially if ventilation becomes too effective and carbon dioxide falls below the apnea threshold. This occurs because breathing control in central sleep apnea is highly sensitive to carbon dioxide levels.
ASV is effective for many patterns of central apnea, but it is not appropriate for every patient. In certain individuals with heart failure and reduced ejection fraction, there have been safety concerns that limit its use in specific clinical contexts. This limitation reflects the need to match ventilatory support to cardiovascular physiology rather than applying the same device broadly.
Supplemental oxygen can improve oxygenation and reduce instability, but it does not always eliminate central apneas and may not address the underlying cause. Medications such as acetazolamide can be helpful, yet their benefits are typically modest and they can produce metabolic or renal side effects because they alter acid-base balance. Implantable therapies such as phrenic nerve stimulation require a procedure and device maintenance, and they do not treat the underlying neurologic or cardiovascular driver of apnea.
Another limitation is that central sleep apnea is often a manifestation of another disorder rather than an isolated disease. If heart failure, opioid exposure, neurologic injury, or high altitude is not addressed, the breathing pattern may remain unstable despite symptomatic therapy. This is why treatment often combines direct control of nocturnal breathing with broader management of the disease process that is disturbing respiratory regulation.
Conclusion
Central sleep apnea is treated by stabilizing the physiology of breathing control and, when possible, correcting the underlying cause. Common approaches include CPAP, adaptive servo-ventilation, bilevel support, supplemental oxygen, and selected medications such as acetazolamide. In more persistent or refractory cases, phrenic nerve stimulation may provide a procedural solution by pacing diaphragmatic activity during sleep. Supportive management and treatment of associated conditions are also central to long-term control.
These therapies differ in method, but they share a common goal: reduce the instability in respiratory drive that leads to central pauses, normalize gas exchange, and protect sleep continuity and organ function. The choice of treatment depends on the cause of the apnea, the severity of ventilatory instability, and the patient’s broader medical context. Central sleep apnea is therefore managed by addressing both the breathing pattern itself and the physiological systems that generate it.